- AstraZeneca India’s net income for the third quarter rose to 308.5 million rupees, marking a 95% increase year-over-year.
- The company’s revenue reached 4.4 billion rupees, a significant 44% rise compared to the previous year.
- Total costs for the quarter amounted to 3.73 billion rupees, reflecting a 26% increase from the prior year.
- Investment analysts showed a neutral position with 0 buys, 0 holds, and 0 sells reported.
- These financial comparisons are based on the company’s original disclosures from past results.
A look at Astrazeneca Pharma India Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 4 | |
| Growth | 3 | |
| Resilience | 5 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.6 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
According to Smartkarma Smart Scores, Astrazeneca Pharma India shows promise in the long term. With a high score in resilience and dividends, the company demonstrates stability and a commitment to rewarding its investors. Additionally, a strong momentum score indicates positive market sentiment towards the company’s performance. While the growth score is not the highest, Astrazeneca Pharma India still shows potential for development and expansion in the future.
Astrazeneca Pharma India Ltd, known for manufacturing a range of drugs and chemicals, including popular products like “Betaloc Durules” and “Theobric,” has received varying scores across different factors. The company’s ability to weather challenges and provide dividends to investors is highly regarded. With a focus on growth and momentum, Astrazeneca Pharma India aims to continue its position as a key player in the pharmaceutical industry.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
